Changes

no edit summary
Line 2,394: Line 2,394:  
|}<br />
 
|}<br />
   −
==Gene-Specific Pages (IN PROCESS OF AUTOMATING - HOLD ON VOLUNTEERING)==
+
==WHO Central Nervous System Tumours  (5th ed.) Content==
{| class="wikitable sortable"
+
{| class="wikitable"
!'''Gene'''
+
|-
!'''Author'''
+
!'''Disease'''!!'''Page Type'''!!'''Author'''
 
!'''Date Assigned to Author'''
 
!'''Date Assigned to Author'''
 
!'''Target Completion Date'''
 
!'''Target Completion Date'''
 
!'''Author Content (Pending or Complete)'''
 
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
+
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Associate Editor'''
   
!'''Date of Last Editor Review'''
 
!'''Date of Last Editor Review'''
 
!'''Notes'''
 
!'''Notes'''
|-
+
|- |Astrocytoma, IDH-mutant||Disease||
|BCR
+
|
|Brian Davis
+
|
 
|
 
|
 
|
 
|
|Complete
  −
|8/10/18
   
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
|ABL1
+
|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted||Disease||
|Brian Davis
+
|
 +
|
 
|
 
|
 
|
 
|
|Complete
  −
|4/16/19
   
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
|RUNX1
+
|Glioblastoma, IDH-wildtype||Disease||
|Brian Davis
+
|
 +
|
 
|
 
|
 
|
 
|
|Complete
  −
|6/9/19
   
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
|RUNX1T1
+
|Diffuse astrocytoma, MYB- or MYBL1-altered||Disease||
|Brian Davis
+
|
 +
|
 
|
 
|
 
|
 
|
|Complete
  −
|5/23/19
   
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
|MYH11
+
|Angiocentric glioma||Disease||
|Brian Davis
+
|
 +
|
 
|
 
|
 
|
 
|
|Complete
  −
|8/6/18
   
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
|FLT3
+
|Polymorphous low-grade neuroepithelial tumour of the young||Disease||
|Kay Weng Choy
+
|
 
|
 
|
 
|
 
|
|Complete
   
|
 
|
 
|
 
|
Line 2,466: Line 2,458:  
|
 
|
 
|-
 
|-
|NPM1
+
|Diffuse low-grade glioma, MAPK pathway-altered||Disease||
|Kay Weng Choy
+
|
 
|
 
|
 
|
 
|
|Complete
   
|
 
|
 
|
 
|
Line 2,476: Line 2,467:  
|
 
|
 
|-
 
|-
|TP53
+
|Diffuse midline glioma, H3 K27-altered||Disease||
|Kay Weng Choy
+
|
 
|
 
|
 
|
 
|
|Complete
   
|
 
|
 
|
 
|
Line 2,486: Line 2,476:  
|
 
|
 
|-
 
|-
|DNMT3A
+
|Diffuse hemispheric glioma, H3 G34-mutant||Disease||
|Kay Weng Choy
+
|
 
|
 
|
 
|
 
|
|Complete
   
|
 
|
 
|
 
|
Line 2,496: Line 2,485:  
|
 
|
 
|-
 
|-
|CEBPA
+
|Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype||Disease||
|Gordana
+
|
 
|
 
|
 
|
 
|
|Complete
   
|
 
|
 
|
 
|
Line 2,506: Line 2,494:  
|
 
|
 
|-
 
|-
|IDH1
+
|Infant-type hemispheric glioma||Disease||
|Paul De Fazio
+
|
 
|
 
|
 
|
 
|
|Complete
   
|
 
|
 
|
 
|
Line 2,516: Line 2,503:  
|
 
|
 
|-
 
|-
|IDH2
+
|Pilocytic astrocytoma||Disease||
|Paul De Fazio
+
|
 
|
 
|
 
|
 
|
|Complete
   
|
 
|
 
|
 
|
Line 2,526: Line 2,512:  
|
 
|
 
|-
 
|-
|PML
+
|High-grade astrocytoma with piloid features||Disease||
|Brian Davis
+
|
 +
|
 
|
 
|
 
|
 
|
|Complete
  −
|12/5/18
   
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
|RARA
+
|Pleomorphic xanthoastrocytoma||Disease||
|Brian Davis
+
|
 +
|
 
|
 
|
 
|
 
|
|Complete
  −
|8/3/18
   
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
|ETV6
+
|Subependymal giant cell astrocytoma||Disease||
|Brian Davis
   
|
 
|
 
|
 
|
|Complete
  −
|6/9/19
   
|
 
|
 
|
 
|
 
|
 
|
|-
  −
|KIT
  −
|Brian Davis
   
|
 
|
 
|
 
|
|Complete
+
|-
|10/1/18
+
|Chordoid glioma||Disease||
 
|
 
|
 
|
 
|
|
  −
|-
  −
|CBFB
  −
|Brian Davis
   
|
 
|
 
|
 
|
|Complete
  −
|8/2/18
   
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
|GATA2
+
|Astroblastoma, MN1-altered||Disease||
|Kay Weng Choy
+
|
 
|
 
|
 
|
 
|
|Complete
   
|
 
|
 
|
 
|
Line 2,586: Line 2,557:  
|
 
|
 
|-
 
|-
|PTEN
+
|Ganglioglioma||Disease||
|Beth Pitel
+
|
 
|
 
|
 
|
 
|
|Pending
   
|
 
|
 
|
 
|
Line 2,596: Line 2,566:  
|
 
|
 
|-
 
|-
|MLTT3
+
|Gangliocytoma||Disease||
 
|
 
|
 
|
 
|
Line 2,604: Line 2,574:  
|
 
|
 
|
 
|
 +
|-
 +
|Desmoplastic infantile ganglioglioma / desmoplastic infantile astrocytoma||Disease||
 
|
 
|
|-
  −
|MECOM
  −
|Brian Davis
   
|
 
|
 
|
 
|
|Pending
   
|
 
|
 
|
 
|
Line 2,616: Line 2,584:  
|
 
|
 
|-
 
|-
|FGFR1(FLT2)
+
|Dysembryoplastic neuroepithelial tumour||Disease||
|Brian Davis
+
|
 
|
 
|
 
|
 
|
|Pending
   
|
 
|
 
|
 
|
Line 2,626: Line 2,593:  
|
 
|
 
|-
 
|-
|KMT2A
+
|Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters||Disease||
 
|
 
|
 
|
 
|
Line 2,634: Line 2,601:  
|
 
|
 
|
 
|
 +
|-
 +
|Papillary glioneuronal tumour||Disease||
 
|
 
|
|-
  −
|DEK
  −
|Wahab A. Khan
   
|
 
|
 
|
 
|
|Pending
   
|
 
|
 
|
 
|
Line 2,646: Line 2,611:  
|
 
|
 
|-
 
|-
|NUP214
+
|Rosette-forming glioneuronal tumour||Disease||
|Wahab A. Khan
+
|
 
|
 
|
 
|
 
|
|Pending
   
|
 
|
 
|
 
|
Line 2,656: Line 2,620:  
|
 
|
 
|-
 
|-
|RBM15
+
|Myxoid glioneuronal tumour||Disease||
 
|
 
|
 
|
 
|
Line 2,664: Line 2,628:  
|
 
|
 
|
 
|
 +
|-
 +
|Diffuse leptomeningeal glioneuronal tumour||Disease||
 
|
 
|
|-
  −
|MKL1
   
|
 
|
 
|
 
|
Line 2,673: Line 2,637:  
|
 
|
 
|
 
|
 +
|-
 +
|Multinodular and vacuolating neuronal tumour||Disease||
 
|
 
|
 
|
 
|
|-
  −
|DDX41
  −
|Ying Zou
  −
|8/7/20
   
|
 
|
|Pending
   
|
 
|
 
|
 
|
Line 2,686: Line 2,647:  
|
 
|
 
|-
 
|-
|ANKRD26
+
|Dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease)||Disease||
|
   
|
 
|
 
|
 
|
Line 2,696: Line 2,656:  
|
 
|
 
|-
 
|-
|CUX1
+
|Central neurocytoma||Disease||
|
   
|
 
|
 
|
 
|
Line 2,706: Line 2,665:  
|
 
|
 
|-
 
|-
|TET2
+
|Extraventricular neurocytoma||Disease||
|
   
|
 
|
 
|
 
|
Line 2,716: Line 2,674:  
|
 
|
 
|-
 
|-
|EZH2
+
|Cerebellar liponeurocytoma||Disease||
|
   
|
 
|
 
|
 
|
Line 2,726: Line 2,683:  
|
 
|
 
|-
 
|-
|FOXP1
+
|Supratentorial ependymoma||Disease||
|
   
|
 
|
 
|
 
|
Line 2,736: Line 2,692:  
|
 
|
 
|-
 
|-
|MYC
+
|Supratentorial ependymoma, ZFTA fusion-positive||Disease||
|
   
|
 
|
 
|
 
|
Line 2,746: Line 2,701:  
|
 
|
 
|-
 
|-
|JAK2
+
|Supratentorial ependymoma, YAP1 fusion-positive||Disease||
 
|
 
|
 
|
 
|
Line 2,754: Line 2,709:  
|
 
|
 
|
 
|
 +
|-
 +
|Posterior fossa ependymoma||Disease||
 
|
 
|
|-
  −
|WT1
  −
|DONE
   
|
 
|
 
|
 
|
|DONE
   
|
 
|
 
|
 
|
Line 2,766: Line 2,719:  
|
 
|
 
|-
 
|-
|CBL
+
|Posterior fossa group A (PFA) ependymoma||Disease||
|
   
|
 
|
 
|
 
|
Line 2,776: Line 2,728:  
|
 
|
 
|-
 
|-
|NF1
+
|Posterior fossa group B (PFB) ependymoma||Disease||
|
   
|
 
|
 
|
 
|
Line 2,786: Line 2,737:  
|
 
|
 
|-
 
|-
|SUZ12
+
|Spinal ependymoma||Disease||
|
   
|
 
|
 
|
 
|
Line 2,796: Line 2,746:  
|
 
|
 
|-
 
|-
|ERG
+
|Spinal ependymoma, MYCN-amplified||Disease||
|
   
|
 
|
 
|
 
|
Line 2,806: Line 2,755:  
|
 
|
 
|-
 
|-
|EST2
+
|Myxopapillary ependymoma||Disease||
|
   
|
 
|
 
|
 
|
Line 2,816: Line 2,764:  
|
 
|
 
|-
 
|-
|RPS14
+
|Subependymoma||Disease||
|
   
|
 
|
 
|
 
|
Line 2,826: Line 2,773:  
|
 
|
 
|-
 
|-
|RB1
+
|Choroid plexus papilloma||Disease||
|
   
|
 
|
 
|
 
|
Line 2,836: Line 2,782:  
|
 
|
 
|-
 
|-
|MPL
+
|Atypical choroid plexus papilloma||Disease||
|
   
|
 
|
 
|
 
|
Line 2,846: Line 2,791:  
|
 
|
 
|-
 
|-
|CHGA
+
|Choroid plexus carcinoma||Disease||
|
   
|
 
|
 
|
 
|
Line 2,856: Line 2,800:  
|
 
|
 
|-
 
|-
|CDH1
+
|Medulloblastoma, WNT-activated||Disease||
|
   
|
 
|
 
|
 
|
Line 2,866: Line 2,809:  
|
 
|
 
|-
 
|-
|SRSF2
+
|Medulloblastoma, SHH-activated and TP53-wildtype||Disease||
|
   
|
 
|
 
|
 
|
Line 2,876: Line 2,818:  
|
 
|
 
|-
 
|-
|DNMT1
+
|Medulloblastoma, SHH-activated and TP53-mutant||Disease||
|
   
|
 
|
 
|
 
|
Line 2,886: Line 2,827:  
|
 
|
 
|-
 
|-
|PRDX2
+
|Medulloblastoma, non-WNT/non-SHH||Disease||
|
   
|
 
|
 
|
 
|
Line 2,896: Line 2,836:  
|
 
|
 
|-
 
|-
|ASXL1
+
|Medulloblastoma, histologically defined||Disease||
|DONE
+
|
 
|
 
|
 
|
 
|
|DONE
   
|
 
|
 
|
 
|
Line 2,906: Line 2,845:  
|
 
|
 
|-
 
|-
|MN1
+
|Atypical teratoid/rhabdoid tumour||Disease||
|
   
|
 
|
 
|
 
|
Line 2,916: Line 2,854:  
|
 
|
 
|-
 
|-
|SF3A1
+
|Cribriform neuroepithelial tumour||Disease||
 
|
 
|
 
|
 
|
Line 2,924: Line 2,862:  
|
 
|
 
|
 
|
 +
|-
 +
|Embryonal tumour with multilayered rosettes||Disease||
 
|
 
|
|-
  −
|EP300
   
|
 
|
 
|
 
|
Line 2,933: Line 2,871:  
|
 
|
 
|
 
|
 +
|-
 +
|CNS neuroblastoma, FOXR2-activated||Disease||
 
|
 
|
 
|
 
|
|-
  −
|JARID2
   
|
 
|
 
|
 
|
Line 2,942: Line 2,880:  
|
 
|
 
|
 
|
 +
|-
 +
|CNS tumour with BCOR internal tandem duplication||Disease||
 
|
 
|
 
|
 
|
 
|
 
|
|-
  −
|BRCA1
   
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 +
|-
 +
|CNS embryonal tumour NEC/NOS||Disease||
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|
|-
  −
|BRCA2
   
|
 
|
 
|
 
|
 
|
 
|
 +
|-
 +
|Pineocytoma||Disease||
 
|
 
|
 
|
 
|
Line 2,965: Line 2,905:  
|
 
|
 
|
 
|
|-
   
|
 
|
 
|
 
|
 +
|-
 +
|Pineal parenchymal tumour of intermediate differentiation||Disease||
 
|
 
|
 
|
 
|
Line 2,976: Line 2,917:  
|
 
|
 
|-
 
|-
 +
|Pineoblastoma||Disease||
 +
|
 
|
 
|
 
|
 
|
Line 2,982: Line 2,925:  
|
 
|
 
|
 
|
|
+
|-
|
+
|Papillary tumour of the pineal region||Disease||
|
  −
|}
  −
 
  −
==WHO Central Nervous System Tumours  (5th ed.) Content==
  −
{| class="wikitable"
  −
|-
  −
!'''Disease'''!!'''Page Type'''!!'''Author'''
  −
!'''Date Assigned to Author'''
  −
!'''Target Completion Date'''
  −
!'''Author Content (Pending or Complete)'''
  −
!'''Date Completed by Author'''!!'''Associate Editor'''
  −
!'''Date of Last Editor Review'''
  −
!'''Notes'''
  −
|- |Astrocytoma, IDH-mutant||Disease||
   
|
 
|
 
|
 
|
Line 3,006: Line 2,935:  
|
 
|
 
|-
 
|-
|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted||Disease||
+
|Desmoplastic myxoid tumour of the pineal region, SMARCB1-mutant||Disease||
 
|
 
|
 
|
 
|
Line 3,015: Line 2,944:  
|
 
|
 
|-
 
|-
|Glioblastoma, IDH-wildtype||Disease||
+
|Schwannoma||Disease||
 
|
 
|
 
|
 
|
Line 3,024: Line 2,953:  
|
 
|
 
|-
 
|-
|Diffuse astrocytoma, MYB- or MYBL1-altered||Disease||
+
|Neurofibroma||Disease||
 
|
 
|
 
|
 
|
Line 3,033: Line 2,962:  
|
 
|
 
|-
 
|-
|Angiocentric glioma||Disease||
+
|Perineurioma||Disease||
 
|
 
|
 
|
 
|
Line 3,042: Line 2,971:  
|
 
|
 
|-
 
|-
|Polymorphous low-grade neuroepithelial tumour of the young||Disease||
+
|Hybrid nerve sheath tumours||Disease||
 
|
 
|
 
|
 
|
Line 3,051: Line 2,980:  
|
 
|
 
|-
 
|-
|Diffuse low-grade glioma, MAPK pathway-altered||Disease||
+
|Malignant melanotic nerve sheath tumour||Disease||
 
|
 
|
 
|
 
|
Line 3,060: Line 2,989:  
|
 
|
 
|-
 
|-
|Diffuse midline glioma, H3 K27-altered||Disease||
+
|Malignant peripheral nerve sheath tumour||Disease||
 
|
 
|
 
|
 
|
Line 3,069: Line 2,998:  
|
 
|
 
|-
 
|-
|Diffuse hemispheric glioma, H3 G34-mutant||Disease||
+
|Cauda equina neuroendocrine tumour (previously paraganglioma)||Disease||
 
|
 
|
 
|
 
|
Line 3,078: Line 3,007:  
|
 
|
 
|-
 
|-
|Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype||Disease||
+
|Meningioma||Disease||
 
|
 
|
 
|
 
|
Line 3,087: Line 3,016:  
|
 
|
 
|-
 
|-
|Infant-type hemispheric glioma||Disease||
+
|Solitary fibrous tumour||Disease||
 
|
 
|
 
|
 
|
Line 3,096: Line 3,025:  
|
 
|
 
|-
 
|-
|Pilocytic astrocytoma||Disease||
+
|Haemangiomas and vascular malformations||Disease||
 
|
 
|
 
|
 
|
Line 3,105: Line 3,034:  
|
 
|
 
|-
 
|-
|High-grade astrocytoma with piloid features||Disease||
+
|Haemangioblastoma||Disease||
 
|
 
|
 
|
 
|
Line 3,114: Line 3,043:  
|
 
|
 
|-
 
|-
|Pleomorphic xanthoastrocytoma||Disease||
+
|Rhabdomyosarcoma||Disease||
 
|
 
|
 
|
 
|
Line 3,123: Line 3,052:  
|
 
|
 
|-
 
|-
|Subependymal giant cell astrocytoma||Disease||
+
|Intracranial mesenchymal tumour, FET::CREB fusion-positive||Disease||
 
|
 
|
 
|
 
|
Line 3,132: Line 3,061:  
|
 
|
 
|-
 
|-
|Chordoid glioma||Disease||
+
|CIC-rearranged sarcoma||Disease||
 
|
 
|
 
|
 
|
Line 3,141: Line 3,070:  
|
 
|
 
|-
 
|-
|Astroblastoma, MN1-altered||Disease||
+
|Primary intracranial sarcoma, DICER1-mutant||Disease||
 
|
 
|
 
|
 
|
Line 3,150: Line 3,079:  
|
 
|
 
|-
 
|-
|Ganglioglioma||Disease||
+
|Ewing sarcoma||Disease||
 
|
 
|
 
|
 
|
Line 3,159: Line 3,088:  
|
 
|
 
|-
 
|-
|Gangliocytoma||Disease||
+
|Mesenchymal chondrosarcoma||Disease||
 
|
 
|
 
|
 
|
Line 3,168: Line 3,097:  
|
 
|
 
|-
 
|-
|Desmoplastic infantile ganglioglioma / desmoplastic infantile astrocytoma||Disease||
+
|Chondrosarcoma||Disease||
 
|
 
|
 
|
 
|
Line 3,177: Line 3,106:  
|
 
|
 
|-
 
|-
|Dysembryoplastic neuroepithelial tumour||Disease||
+
|Chordoma||Disease||
 
|
 
|
 
|
 
|
Line 3,186: Line 3,115:  
|
 
|
 
|-
 
|-
|Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters||Disease||
+
|Diffuse meningeal melanocytic neoplasms: Melanocytosis and melanomatosis||Disease||
 
|
 
|
 
|
 
|
Line 3,195: Line 3,124:  
|
 
|
 
|-
 
|-
|Papillary glioneuronal tumour||Disease||
+
|Circumscribed meningeal melanocytic neoplasms: Melanocytoma and melanoma||Disease||
 
|
 
|
 
|
 
|
Line 3,204: Line 3,133:  
|
 
|
 
|-
 
|-
|Rosette-forming glioneuronal tumour||Disease||
+
|Primary diffuse large B-cell lymphoma of the CNS||Disease||
 
|
 
|
 
|
 
|
Line 3,213: Line 3,142:  
|
 
|
 
|-
 
|-
|Myxoid glioneuronal tumour||Disease||
+
|Immunodeficiency-associated CNS lymphomas||Disease||
 
|
 
|
 
|
 
|
Line 3,222: Line 3,151:  
|
 
|
 
|-
 
|-
|Diffuse leptomeningeal glioneuronal tumour||Disease||
+
|Lymphomatoid granulomatosis||Disease||
 
|
 
|
 
|
 
|
Line 3,231: Line 3,160:  
|
 
|
 
|-
 
|-
|Multinodular and vacuolating neuronal tumour||Disease||
+
|Intravascular large B-cell lymphoma||Disease||
 
|
 
|
 
|
 
|
Line 3,240: Line 3,169:  
|
 
|
 
|-
 
|-
|Dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease)||Disease||
+
|MALT lymphoma of the dura||Disease||
 
|
 
|
 
|
 
|
Line 3,249: Line 3,178:  
|
 
|
 
|-
 
|-
|Central neurocytoma||Disease||
+
|Other low-grade B-cell lymphomas of the CNS||Disease||
 
|
 
|
 
|
 
|
Line 3,258: Line 3,187:  
|
 
|
 
|-
 
|-
|Extraventricular neurocytoma||Disease||
+
|Anaplastic large cell lymphoma (ALK+/ALK−)||Disease||
 
|
 
|
 
|
 
|
Line 3,267: Line 3,196:  
|
 
|
 
|-
 
|-
|Cerebellar liponeurocytoma||Disease||
+
|T-cell and NK/T-cell lymphomas||Disease||
 
|
 
|
 
|
 
|
Line 3,276: Line 3,205:  
|
 
|
 
|-
 
|-
|Supratentorial ependymoma||Disease||
+
|Erdheim-Chester disease||Disease||
 
|
 
|
 
|
 
|
Line 3,285: Line 3,214:  
|
 
|
 
|-
 
|-
|Supratentorial ependymoma, ZFTA fusion-positive||Disease||
+
|Rosai-Dorfman disease||Disease||
 
|
 
|
 
|
 
|
Line 3,294: Line 3,223:  
|
 
|
 
|-
 
|-
|Supratentorial ependymoma, YAP1 fusion-positive||Disease||
+
|Juvenile xanthogranuloma||Disease||
 
|
 
|
 
|
 
|
Line 3,303: Line 3,232:  
|
 
|
 
|-
 
|-
|Posterior fossa ependymoma||Disease||
+
|Langerhans cell histiocytosis||Disease||
 
|
 
|
 
|
 
|
Line 3,312: Line 3,241:  
|
 
|
 
|-
 
|-
|Posterior fossa group A (PFA) ependymoma||Disease||
+
|Histiocytic sarcoma||Disease||
 
|
 
|
 
|
 
|
Line 3,321: Line 3,250:  
|
 
|
 
|-
 
|-
|Posterior fossa group B (PFB) ependymoma||Disease||
+
|Germ cell tumours of the CNS||Disease||
 
|
 
|
 
|
 
|
Line 3,330: Line 3,259:  
|
 
|
 
|-
 
|-
|Spinal ependymoma||Disease||
+
|Adamantinomatous craniopharyngioma||Disease||
 
|
 
|
 
|
 
|
Line 3,339: Line 3,268:  
|
 
|
 
|-
 
|-
|Spinal ependymoma, MYCN-amplified||Disease||
+
|Papillary craniopharyngioma||Disease||
 
|
 
|
 
|
 
|
Line 3,348: Line 3,277:  
|
 
|
 
|-
 
|-
|Myxopapillary ependymoma||Disease||
+
|Pituicytoma, granular cell tumour of the sellar region, and spindle cell oncocytoma||Disease||
 
|
 
|
 
|
 
|
Line 3,357: Line 3,286:  
|
 
|
 
|-
 
|-
|Subependymoma||Disease||
+
|Pituitary adenoma / pituitary neuroendocrine tumour||Disease||
 
|
 
|
 
|
 
|
Line 3,366: Line 3,295:  
|
 
|
 
|-
 
|-
|Choroid plexus papilloma||Disease||
+
|Pituitary blastoma||Disease||
 
|
 
|
 
|
 
|
Line 3,375: Line 3,304:  
|
 
|
 
|-
 
|-
|Atypical choroid plexus papilloma||Disease||
+
|Metastases to the brain and spinal cord parenchyma||Disease||
 
|
 
|
 
|
 
|
Line 3,384: Line 3,313:  
|
 
|
 
|-
 
|-
|Choroid plexus carcinoma||Disease||
+
|Metastases to the meninges||Disease||
 
|
 
|
 
|
 
|
Line 3,393: Line 3,322:  
|
 
|
 
|-
 
|-
|Medulloblastoma, WNT-activated||Disease||
+
|Neurofibromatosis type 1||Disease||
 
|
 
|
 
|
 
|
Line 3,402: Line 3,331:  
|
 
|
 
|-
 
|-
|Medulloblastoma, SHH-activated and TP53-wildtype||Disease||
+
|Neurofibromatosis type 2||Disease||
 
|
 
|
 
|
 
|
Line 3,411: Line 3,340:  
|
 
|
 
|-
 
|-
|Medulloblastoma, SHH-activated and TP53-mutant||Disease||
+
|Schwannomatosis||Disease||
 
|
 
|
 
|
 
|
Line 3,420: Line 3,349:  
|
 
|
 
|-
 
|-
|Medulloblastoma, non-WNT/non-SHH||Disease||
+
|Von Hippel-Lindau syndrome||Disease||
 
|
 
|
 
|
 
|
Line 3,429: Line 3,358:  
|
 
|
 
|-
 
|-
|Medulloblastoma, histologically defined||Disease||
+
|Tuberous sclerosis||Disease||
 
|
 
|
 
|
 
|
Line 3,438: Line 3,367:  
|
 
|
 
|-
 
|-
|Atypical teratoid/rhabdoid tumour||Disease||
+
|Li-Fraumeni syndrome||Disease||
 
|
 
|
 
|
 
|
Line 3,447: Line 3,376:  
|
 
|
 
|-
 
|-
|Cribriform neuroepithelial tumour||Disease||
+
|Cowden syndrome||Disease||
 
|
 
|
 
|
 
|
Line 3,456: Line 3,385:  
|
 
|
 
|-
 
|-
|Embryonal tumour with multilayered rosettes||Disease||
+
|Constitutional mismatch repair deficiency syndrome||Disease||
 
|
 
|
 
|
 
|
Line 3,465: Line 3,394:  
|
 
|
 
|-
 
|-
|CNS neuroblastoma, FOXR2-activated||Disease||
+
|Familial adenomatous polyposis 1||Disease||
 
|
 
|
 
|
 
|
Line 3,474: Line 3,403:  
|
 
|
 
|-
 
|-
|CNS tumour with BCOR internal tandem duplication||Disease||
+
|Naevoid basal cell carcinoma syndrome||Disease||
 
|
 
|
 
|
 
|
Line 3,483: Line 3,412:  
|
 
|
 
|-
 
|-
|CNS embryonal tumour NEC/NOS||Disease||
+
|Rhabdoid tumour predisposition syndrome||Disease||
 
|
 
|
 
|
 
|
Line 3,492: Line 3,421:  
|
 
|
 
|-
 
|-
|Pineocytoma||Disease||
+
|Carney complex||Disease||
 
|
 
|
 
|
 
|
Line 3,501: Line 3,430:  
|
 
|
 
|-
 
|-
|Pineal parenchymal tumour of intermediate differentiation||Disease||
+
|DICER1 syndrome||Disease||
 
|
 
|
 
|
 
|
Line 3,510: Line 3,439:  
|
 
|
 
|-
 
|-
|Pineoblastoma||Disease||
+
|Familial paraganglioma syndromes||Disease||
 
|
 
|
 
|
 
|
Line 3,519: Line 3,448:  
|
 
|
 
|-
 
|-
|Papillary tumour of the pineal region||Disease||
+
|Melanoma-astrocytoma syndrome||Disease||
 
|
 
|
 
|
 
|
Line 3,528: Line 3,457:  
|
 
|
 
|-
 
|-
|Desmoplastic myxoid tumour of the pineal region, SMARCB1-mutant||Disease||
+
|Familial retinoblastoma||Disease||
 
|
 
|
 
|
 
|
Line 3,537: Line 3,466:  
|
 
|
 
|-
 
|-
|Schwannoma||Disease||
+
|BAP1 tumour predisposition syndrome||Disease||
 
|
 
|
 
|
 
|
Line 3,546: Line 3,475:  
|
 
|
 
|-
 
|-
|Neurofibroma||Disease||
+
|Fanconi anaemia||Disease||
 
|
 
|
 
|
 
|
Line 3,555: Line 3,484:  
|
 
|
 
|-
 
|-
|Perineurioma||Disease||
+
|ELP1-medulloblastoma syndrome||Disease||
 
|
 
|
 
|
 
|
Line 3,564: Line 3,493:  
|
 
|
 
|-
 
|-
|Hybrid nerve sheath tumours||Disease||
+
|}
 +
 
 +
==WHO Breast tumours (5th ed.) Content==
 +
{| class="wikitable"
 +
|-
 +
!'''Disease'''!!'''Page Type'''!!'''Author'''
 +
!'''Date Assigned to Author'''
 +
!'''Target Completion Date'''
 +
!'''Author Content (Pending or Complete)'''
 +
!'''Date Completed by Author'''!!'''Associate Editor'''
 +
!'''Date of Last Editor Review'''
 +
!'''Notes'''
 +
|- |Usual ductal hyperplasia||Disease||
 
|
 
|
 
|
 
|
Line 3,573: Line 3,514:  
|
 
|
 
|-
 
|-
|Malignant melanotic nerve sheath tumour||Disease||
+
|Columnar cell lesions, including flat epithelial atypia||Disease||
 
|
 
|
 
|
 
|
Line 3,582: Line 3,523:  
|
 
|
 
|-
 
|-
|Malignant peripheral nerve sheath tumour||Disease||
+
|Atypical ductal hyperplasia||Disease||
 
|
 
|
 
|
 
|
Line 3,591: Line 3,532:  
|
 
|
 
|-
 
|-
|Cauda equina neuroendocrine tumour (previously paraganglioma)||Disease||
+
|Sclerosing adenosis||Disease||
 
|
 
|
 
|
 
|
Line 3,600: Line 3,541:  
|
 
|
 
|-
 
|-
|Meningioma||Disease||
+
|Apocrine adenosis and adenoma||Disease||
 
|
 
|
 
|
 
|
Line 3,609: Line 3,550:  
|
 
|
 
|-
 
|-
|Solitary fibrous tumour||Disease||
+
|Microglandular adenosis||Disease||
 
|
 
|
 
|
 
|
Line 3,618: Line 3,559:  
|
 
|
 
|-
 
|-
|Haemangiomas and vascular malformations||Disease||
+
|Radial scar / complex sclerosing lesion||Disease||
 
|
 
|
 
|
 
|
Line 3,627: Line 3,568:  
|
 
|
 
|-
 
|-
|Haemangioblastoma||Disease||
+
|Tubular adenoma||Disease||
 
|
 
|
 
|
 
|
Line 3,636: Line 3,577:  
|
 
|
 
|-
 
|-
|Rhabdomyosarcoma||Disease||
+
|Lactating adenoma||Disease||
 
|
 
|
 
|
 
|
Line 3,645: Line 3,586:  
|
 
|
 
|-
 
|-
|Intracranial mesenchymal tumour, FET::CREB fusion-positive||Disease||
+
|Ductal adenoma||Disease||
 
|
 
|
 
|
 
|
Line 3,654: Line 3,595:  
|
 
|
 
|-
 
|-
|CIC-rearranged sarcoma||Disease||
+
|Pleomorphic adenoma||Disease||
 
|
 
|
 
|
 
|
Line 3,663: Line 3,604:  
|
 
|
 
|-
 
|-
|Primary intracranial sarcoma, DICER1-mutant||Disease||
+
|Adenomyoepithelioma||Disease||
 
|
 
|
 
|
 
|
Line 3,672: Line 3,613:  
|
 
|
 
|-
 
|-
|Ewing sarcoma||Disease||
+
|Malignant adenomyoepithelioma||Disease||
 
|
 
|
 
|
 
|
Line 3,681: Line 3,622:  
|
 
|
 
|-
 
|-
|Mesenchymal chondrosarcoma||Disease||
+
|Intraductal papilloma||Disease||
 
|
 
|
 
|
 
|
Line 3,690: Line 3,631:  
|
 
|
 
|-
 
|-
|Chondrosarcoma||Disease||
+
|Papillary ductal carcinoma in situ||Disease||
 
|
 
|
 
|
 
|
Line 3,699: Line 3,640:  
|
 
|
 
|-
 
|-
|Chordoma||Disease||
+
|Encapsulated papillary carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 3,708: Line 3,649:  
|
 
|
 
|-
 
|-
|Diffuse meningeal melanocytic neoplasms: Melanocytosis and melanomatosis||Disease||
+
|Solid papillary carcinoma (in situ and invasive)||Disease||
 
|
 
|
 
|
 
|
Line 3,717: Line 3,658:  
|
 
|
 
|-
 
|-
|Circumscribed meningeal melanocytic neoplasms: Melanocytoma and melanoma||Disease||
+
|Invasive papillary carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 3,726: Line 3,667:  
|
 
|
 
|-
 
|-
|Primary diffuse large B-cell lymphoma of the CNS||Disease||
+
|Atypical lobular hyperplasia||Disease||
 
|
 
|
 
|
 
|
Line 3,735: Line 3,676:  
|
 
|
 
|-
 
|-
|Immunodeficiency-associated CNS lymphomas||Disease||
+
|Lobular carcinoma in situ||Disease||
 
|
 
|
 
|
 
|
Line 3,744: Line 3,685:  
|
 
|
 
|-
 
|-
|Lymphomatoid granulomatosis||Disease||
+
|Ductal carcinoma in situ||Disease||
 
|
 
|
 
|
 
|
Line 3,753: Line 3,694:  
|
 
|
 
|-
 
|-
|Intravascular large B-cell lymphoma||Disease||
+
|Invasive breast carcinoma: General overview||Disease||
 
|
 
|
 
|
 
|
Line 3,762: Line 3,703:  
|
 
|
 
|-
 
|-
|MALT lymphoma of the dura||Disease||
+
|Invasive breast carcinoma of no special type||Disease||
 
|
 
|
 
|
 
|
Line 3,771: Line 3,712:  
|
 
|
 
|-
 
|-
|Other low-grade B-cell lymphomas of the CNS||Disease||
+
|Microinvasive carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 3,780: Line 3,721:  
|
 
|
 
|-
 
|-
|Anaplastic large cell lymphoma (ALK+/ALK−)||Disease||
+
|Invasive lobular carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 3,789: Line 3,730:  
|
 
|
 
|-
 
|-
|T-cell and NK/T-cell lymphomas||Disease||
+
|Tubular carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 3,798: Line 3,739:  
|
 
|
 
|-
 
|-
|Erdheim-Chester disease||Disease||
+
|Cribriform carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 3,807: Line 3,748:  
|
 
|
 
|-
 
|-
|Rosai-Dorfman disease||Disease||
+
|Mucinous carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 3,816: Line 3,757:  
|
 
|
 
|-
 
|-
|Juvenile xanthogranuloma||Disease||
+
|Mucinous cystadenocarcinoma||Disease||
 
|
 
|
 
|
 
|
Line 3,825: Line 3,766:  
|
 
|
 
|-
 
|-
|Langerhans cell histiocytosis||Disease||
+
|Invasive micropapillary carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 3,834: Line 3,775:  
|
 
|
 
|-
 
|-
|Histiocytic sarcoma||Disease||
+
|Carcinoma with apocrine differentiation||Disease||
 
|
 
|
 
|
 
|
Line 3,843: Line 3,784:  
|
 
|
 
|-
 
|-
|Germ cell tumours of the CNS||Disease||
+
|Metaplastic carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 3,852: Line 3,793:  
|
 
|
 
|-
 
|-
|Adamantinomatous craniopharyngioma||Disease||
+
|Acinic cell carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 3,861: Line 3,802:  
|
 
|
 
|-
 
|-
|Papillary craniopharyngioma||Disease||
+
|Adenoid cystic carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 3,870: Line 3,811:  
|
 
|
 
|-
 
|-
|Pituicytoma, granular cell tumour of the sellar region, and spindle cell oncocytoma||Disease||
+
|Secretory carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 3,879: Line 3,820:  
|
 
|
 
|-
 
|-
|Pituitary adenoma / pituitary neuroendocrine tumour||Disease||
+
|Mucoepidermoid carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 3,888: Line 3,829:  
|
 
|
 
|-
 
|-
|Pituitary blastoma||Disease||
+
|Polymorphous adenocarcinoma||Disease||
 
|
 
|
 
|
 
|
Line 3,897: Line 3,838:  
|
 
|
 
|-
 
|-
|Metastases to the brain and spinal cord parenchyma||Disease||
+
|Tall cell carcinoma with reversed polarity||Disease||
 
|
 
|
 
|
 
|
Line 3,906: Line 3,847:  
|
 
|
 
|-
 
|-
|Metastases to the meninges||Disease||
+
|Neuroendocrine tumour||Disease||
 
|
 
|
 
|
 
|
Line 3,915: Line 3,856:  
|
 
|
 
|-
 
|-
|Neurofibromatosis type 1||Disease||
+
|Neuroendocrine carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 3,924: Line 3,865:  
|
 
|
 
|-
 
|-
|Neurofibromatosis type 2||Disease||
+
|Hamartoma||Disease||
 
|
 
|
 
|
 
|
Line 3,933: Line 3,874:  
|
 
|
 
|-
 
|-
|Schwannomatosis||Disease||
+
|Fibroadenoma||Disease||
 
|
 
|
 
|
 
|
Line 3,942: Line 3,883:  
|
 
|
 
|-
 
|-
|Von Hippel-Lindau syndrome||Disease||
+
|Phyllodes tumour||Disease||
 
|
 
|
 
|
 
|
Line 3,951: Line 3,892:  
|
 
|
 
|-
 
|-
|Tuberous sclerosis||Disease||
+
|Syringomatous tumour||Disease||
 
|
 
|
 
|
 
|
Line 3,960: Line 3,901:  
|
 
|
 
|-
 
|-
|Li-Fraumeni syndrome||Disease||
+
|Nipple adenoma||Disease||
 
|
 
|
 
|
 
|
Line 3,969: Line 3,910:  
|
 
|
 
|-
 
|-
|Cowden syndrome||Disease||
+
|Paget disease of the breast||Disease||
 
|
 
|
 
|
 
|
Line 3,978: Line 3,919:  
|
 
|
 
|-
 
|-
|Constitutional mismatch repair deficiency syndrome||Disease||
+
|Haemangioma||Disease||
 
|
 
|
 
|
 
|
Line 3,987: Line 3,928:  
|
 
|
 
|-
 
|-
|Familial adenomatous polyposis 1||Disease||
+
|Angiomatosis||Disease||
 
|
 
|
 
|
 
|
Line 3,996: Line 3,937:  
|
 
|
 
|-
 
|-
|Naevoid basal cell carcinoma syndrome||Disease||
+
|Atypical vascular lesions||Disease||
 
|
 
|
 
|
 
|
Line 4,005: Line 3,946:  
|
 
|
 
|-
 
|-
|Rhabdoid tumour predisposition syndrome||Disease||
+
|Postradiation angiosarcoma of the breast||Disease||
 
|
 
|
 
|
 
|
Line 4,014: Line 3,955:  
|
 
|
 
|-
 
|-
|Carney complex||Disease||
+
|Primary angiosarcoma of the breast||Disease||
 
|
 
|
 
|
 
|
Line 4,023: Line 3,964:  
|
 
|
 
|-
 
|-
|DICER1 syndrome||Disease||
+
|Nodular fasciitis||Disease||
 
|
 
|
 
|
 
|
Line 4,032: Line 3,973:  
|
 
|
 
|-
 
|-
|Familial paraganglioma syndromes||Disease||
+
|Myofibroblastoma||Disease||
 
|
 
|
 
|
 
|
Line 4,041: Line 3,982:  
|
 
|
 
|-
 
|-
|Melanoma-astrocytoma syndrome||Disease||
+
|Desmoid fibromatosis||Disease||
 
|
 
|
 
|
 
|
Line 4,050: Line 3,991:  
|
 
|
 
|-
 
|-
|Familial retinoblastoma||Disease||
+
|Inflammatory myofibroblastic tumour||Disease||
 
|
 
|
 
|
 
|
Line 4,059: Line 4,000:  
|
 
|
 
|-
 
|-
|BAP1 tumour predisposition syndrome||Disease||
+
|Schwannoma||Disease||
 
|
 
|
 
|
 
|
Line 4,068: Line 4,009:  
|
 
|
 
|-
 
|-
|Fanconi anaemia||Disease||
+
|Neurofibroma||Disease||
 
|
 
|
 
|
 
|
Line 4,077: Line 4,018:  
|
 
|
 
|-
 
|-
|ELP1-medulloblastoma syndrome||Disease||
+
|Granular cell tumour||Disease||
 
|
 
|
 
|
 
|
Line 4,086: Line 4,027:  
|
 
|
 
|-
 
|-
|}
+
|Leiomyoma||Disease||
 
  −
==WHO Breast tumours  (5th ed.) Content==
  −
{| class="wikitable"
  −
|-
  −
!'''Disease'''!!'''Page Type'''!!'''Author'''
  −
!'''Date Assigned to Author'''
  −
!'''Target Completion Date'''
  −
!'''Author Content (Pending or Complete)'''
  −
!'''Date Completed by Author'''!!'''Associate Editor'''
  −
!'''Date of Last Editor Review'''
  −
!'''Notes'''
  −
|- |Usual ductal hyperplasia||Disease||
   
|
 
|
 
|
 
|
Line 4,107: Line 4,036:  
|
 
|
 
|-
 
|-
|Columnar cell lesions, including flat epithelial atypia||Disease||
+
|Leiomyosarcoma||Disease||
 
|
 
|
 
|
 
|
Line 4,116: Line 4,045:  
|
 
|
 
|-
 
|-
|Atypical ductal hyperplasia||Disease||
+
|Lipoma||Disease||
 
|
 
|
 
|
 
|
Line 4,125: Line 4,054:  
|
 
|
 
|-
 
|-
|Sclerosing adenosis||Disease||
+
|Angiolipoma||Disease||
 
|
 
|
 
|
 
|
Line 4,134: Line 4,063:  
|
 
|
 
|-
 
|-
|Apocrine adenosis and adenoma||Disease||
+
|Liposarcoma||Disease||
 
|
 
|
 
|
 
|
Line 4,143: Line 4,072:  
|
 
|
 
|-
 
|-
|Microglandular adenosis||Disease||
+
|Pseudoangiomatous stromal hyperplasia||Disease||
 
|
 
|
 
|
 
|
Line 4,152: Line 4,081:  
|
 
|
 
|-
 
|-
|Radial scar / complex sclerosing lesion||Disease||
+
|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)||Disease||
 
|
 
|
 
|
 
|
Line 4,161: Line 4,090:  
|
 
|
 
|-
 
|-
|Tubular adenoma||Disease||
+
|Follicular lymphoma||Disease||
 
|
 
|
 
|
 
|
Line 4,170: Line 4,099:  
|
 
|
 
|-
 
|-
|Lactating adenoma||Disease||
+
|Diffuse large B-cell lymphoma||Disease||
 
|
 
|
 
|
 
|
Line 4,179: Line 4,108:  
|
 
|
 
|-
 
|-
|Ductal adenoma||Disease||
+
|Burkitt lymphoma||Disease||
 
|
 
|
 
|
 
|
Line 4,188: Line 4,117:  
|
 
|
 
|-
 
|-
|Pleomorphic adenoma||Disease||
+
|Breast implant-associated anaplastic large cell lymphoma||Disease||
 
|
 
|
 
|
 
|
Line 4,197: Line 4,126:  
|
 
|
 
|-
 
|-
|Adenomyoepithelioma||Disease||
+
|Gynaecomastia||Disease||
 
|
 
|
 
|
 
|
Line 4,206: Line 4,135:  
|
 
|
 
|-
 
|-
|Malignant adenomyoepithelioma||Disease||
+
|Carcinoma in situ||Disease||
 
|
 
|
 
|
 
|
Line 4,215: Line 4,144:  
|
 
|
 
|-
 
|-
|Intraductal papilloma||Disease||
+
|Invasive carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 4,224: Line 4,153:  
|
 
|
 
|-
 
|-
|Papillary ductal carcinoma in situ||Disease||
+
|Metastases to the breast||Disease||
 
|
 
|
 
|
 
|
Line 4,233: Line 4,162:  
|
 
|
 
|-
 
|-
|Encapsulated papillary carcinoma||Disease||
+
|BRCA1/2-associated hereditary breast and ovarian cancer syndrome||Disease||
 
|
 
|
 
|
 
|
Line 4,242: Line 4,171:  
|
 
|
 
|-
 
|-
|Solid papillary carcinoma (in situ and invasive)||Disease||
+
|Cowden syndrome||Disease||
 
|
 
|
 
|
 
|
Line 4,251: Line 4,180:  
|
 
|
 
|-
 
|-
|Invasive papillary carcinoma||Disease||
+
|Ataxia-telangiectasia||Disease||
 
|
 
|
 
|
 
|
Line 4,260: Line 4,189:  
|
 
|
 
|-
 
|-
|Atypical lobular hyperplasia||Disease||
+
|Li-Fraumeni syndrome, TP53-associated||Disease||
 
|
 
|
 
|
 
|
Line 4,269: Line 4,198:  
|
 
|
 
|-
 
|-
|Lobular carcinoma in situ||Disease||
+
|Li-Fraumeni syndrome, CHEK2-associated||Disease||
 
|
 
|
 
|
 
|
Line 4,278: Line 4,207:  
|
 
|
 
|-
 
|-
|Ductal carcinoma in situ||Disease||
+
|CDH1-associated breast cancer||Disease||
 
|
 
|
 
|
 
|
Line 4,287: Line 4,216:  
|
 
|
 
|-
 
|-
|Invasive breast carcinoma: General overview||Disease||
+
|PALB2-associated cancers||Disease||
 
|
 
|
 
|
 
|
Line 4,296: Line 4,225:  
|
 
|
 
|-
 
|-
|Invasive breast carcinoma of no special type||Disease||
+
|Peutz-Jeghers syndrome||Disease||
 
|
 
|
 
|
 
|
Line 4,305: Line 4,234:  
|
 
|
 
|-
 
|-
|Microinvasive carcinoma||Disease||
+
|Neurofibromatosis type 1||Disease||
 
|
 
|
 
|
 
|
Line 4,314: Line 4,243:  
|
 
|
 
|-
 
|-
|Invasive lobular carcinoma||Disease||
+
|}
|
+
 
|
+
==Gene-Specific Pages (IN PROCESS OF AUTOMATING - HOLD ON VOLUNTEERING)==
 +
{| class="wikitable sortable"
 +
!'''Gene'''
 +
!'''Author'''
 +
!'''Date Assigned to Author'''
 +
!'''Target Completion Date'''
 +
!'''Author Content (Pending or Complete)'''
 +
!'''Date Completed by Author'''
 +
!'''Associate Editor'''
 +
!'''Date of Last Editor Review'''
 +
!'''Notes'''
 +
|-
 +
|BCR
 +
|Brian Davis
 
|
 
|
 
|
 
|
 +
|Complete
 +
|8/10/18
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
|Tubular carcinoma||Disease||
+
|ABL1
|
+
|Brian Davis
|
   
|
 
|
 
|
 
|
 +
|Complete
 +
|4/16/19
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
|Cribriform carcinoma||Disease||
+
|RUNX1
 +
|Brian Davis
 
|
 
|
 
|
 
|
 +
|Complete
 +
|6/9/19
 
|
 
|
 
|
 
|
 
|
 
|
 +
|-
 +
|RUNX1T1
 +
|Brian Davis
 
|
 
|
 
|
 
|
|-
+
|Complete
|Mucinous carcinoma||Disease||
+
|5/23/19
 
|
 
|
 
|
 
|
 
|
 
|
 +
|-
 +
|MYH11
 +
|Brian Davis
 
|
 
|
 +
|
 +
|Complete
 +
|8/6/18
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
|Mucinous cystadenocarcinoma||Disease||
+
|FLT3
|
+
|Kay Weng Choy
 
|
 
|
 
|
 
|
 +
|Complete
 
|
 
|
 
|
 
|
Line 4,359: Line 4,317:  
|
 
|
 
|-
 
|-
|Invasive micropapillary carcinoma||Disease||
+
|NPM1
|
+
|Kay Weng Choy
 
|
 
|
 
|
 
|
 +
|Complete
 
|
 
|
 
|
 
|
Line 4,368: Line 4,327:  
|
 
|
 
|-
 
|-
|Carcinoma with apocrine differentiation||Disease||
+
|TP53
|
+
|Kay Weng Choy
 
|
 
|
 
|
 
|
 +
|Complete
 
|
 
|
 
|
 
|
Line 4,377: Line 4,337:  
|
 
|
 
|-
 
|-
|Metaplastic carcinoma||Disease||
+
|DNMT3A
|
+
|Kay Weng Choy
 
|
 
|
 
|
 
|
 +
|Complete
 
|
 
|
 
|
 
|
Line 4,386: Line 4,347:  
|
 
|
 
|-
 
|-
|Acinic cell carcinoma||Disease||
+
|CEBPA
|
+
|Gordana
 
|
 
|
 
|
 
|
 +
|Complete
 
|
 
|
 
|
 
|
Line 4,395: Line 4,357:  
|
 
|
 
|-
 
|-
|Adenoid cystic carcinoma||Disease||
+
|IDH1
|
+
|Paul De Fazio
 
|
 
|
 
|
 
|
 +
|Complete
 
|
 
|
 
|
 
|
Line 4,404: Line 4,367:  
|
 
|
 
|-
 
|-
|Secretory carcinoma||Disease||
+
|IDH2
|
+
|Paul De Fazio
 
|
 
|
 
|
 
|
 +
|Complete
 
|
 
|
 
|
 
|
Line 4,413: Line 4,377:  
|
 
|
 
|-
 
|-
|Mucoepidermoid carcinoma||Disease||
+
|PML
|
+
|Brian Davis
|
   
|
 
|
 
|
 
|
 +
|Complete
 +
|12/5/18
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
|Polymorphous adenocarcinoma||Disease||
+
|RARA
|
+
|Brian Davis
|
   
|
 
|
 
|
 
|
 +
|Complete
 +
|8/3/18
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
|Tall cell carcinoma with reversed polarity||Disease||
+
|ETV6
|
+
|Brian Davis
|
   
|
 
|
 
|
 
|
 +
|Complete
 +
|6/9/19
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
|Neuroendocrine tumour||Disease||
+
|KIT
|
+
|Brian Davis
|
   
|
 
|
 
|
 
|
 +
|Complete
 +
|10/1/18
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
|Neuroendocrine carcinoma||Disease||
+
|CBFB
|
+
|Brian Davis
|
   
|
 
|
 
|
 
|
 +
|Complete
 +
|8/2/18
 
|
 
|
 
|
 
|
 
|
 
|
 
|-
 
|-
|Hamartoma||Disease||
+
|GATA2
|
+
|Kay Weng Choy
 
|
 
|
 
|
 
|
 +
|Complete
 
|
 
|
 
|
 
|
Line 4,467: Line 4,437:  
|
 
|
 
|-
 
|-
|Fibroadenoma||Disease||
+
|PTEN
 +
|Beth Pitel
 
|
 
|
 
|
 
|
 +
|Pending
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 +
|-
 +
|MLTT3
 
|
 
|
|-
  −
|Phyllodes tumour||Disease||
   
|
 
|
 
|
 
|
Line 4,485: Line 4,457:  
|
 
|
 
|-
 
|-
|Syringomatous tumour||Disease||
+
|MECOM
|
+
|Brian Davis
 
|
 
|
 
|
 
|
 +
|Pending
 
|
 
|
 
|
 
|
Line 4,494: Line 4,467:  
|
 
|
 
|-
 
|-
|Nipple adenoma||Disease||
+
|FGFR1(FLT2)
 +
|Brian Davis
 
|
 
|
 
|
 
|
 +
|Pending
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 +
|-
 +
|KMT2A
 
|
 
|
|-
  −
|Paget disease of the breast||Disease||
   
|
 
|
 
|
 
|
Line 4,512: Line 4,487:  
|
 
|
 
|-
 
|-
|Haemangioma||Disease||
+
|DEK
|
+
|Wahab A. Khan
 
|
 
|
 
|
 
|
 +
|Pending
 
|
 
|
 
|
 
|
Line 4,521: Line 4,497:  
|
 
|
 
|-
 
|-
|Angiomatosis||Disease||
+
|NUP214
 +
|Wahab A. Khan
 
|
 
|
 
|
 
|
 +
|Pending
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 +
|-
 +
|RBM15
 
|
 
|
|-
  −
|Atypical vascular lesions||Disease||
   
|
 
|
 
|
 
|
Line 4,539: Line 4,517:  
|
 
|
 
|-
 
|-
|Postradiation angiosarcoma of the breast||Disease||
+
|MKL1
 +
|
 
|
 
|
 
|
 
|
Line 4,548: Line 4,527:  
|
 
|
 
|-
 
|-
|Primary angiosarcoma of the breast||Disease||
+
|DDX41
|
+
|Ying Zou
 +
|8/7/20
 
|
 
|
 +
|Pending
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 +
|-
 +
|ANKRD26
 
|
 
|
|-
  −
|Nodular fasciitis||Disease||
   
|
 
|
 
|
 
|
Line 4,566: Line 4,547:  
|
 
|
 
|-
 
|-
|Myofibroblastoma||Disease||
+
|CUX1
 +
|
 
|
 
|
 
|
 
|
Line 4,575: Line 4,557:  
|
 
|
 
|-
 
|-
|Desmoid fibromatosis||Disease||
+
|TET2
 +
|
 
|
 
|
 
|
 
|
Line 4,584: Line 4,567:  
|
 
|
 
|-
 
|-
|Inflammatory myofibroblastic tumour||Disease||
+
|EZH2
 +
|
 
|
 
|
 
|
 
|
Line 4,593: Line 4,577:  
|
 
|
 
|-
 
|-
|Schwannoma||Disease||
+
|FOXP1
 +
|
 
|
 
|
 
|
 
|
Line 4,602: Line 4,587:  
|
 
|
 
|-
 
|-
|Neurofibroma||Disease||
+
|MYC
 +
|
 
|
 
|
 
|
 
|
Line 4,611: Line 4,597:  
|
 
|
 
|-
 
|-
|Granular cell tumour||Disease||
+
|JAK2
 +
|
 
|
 
|
 
|
 
|
Line 4,620: Line 4,607:  
|
 
|
 
|-
 
|-
|Leiomyoma||Disease||
+
|WT1
 +
|DONE
 
|
 
|
 
|
 
|
 +
|DONE
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 +
|-
 +
|CBL
 
|
 
|
|-
  −
|Leiomyosarcoma||Disease||
   
|
 
|
 
|
 
|
Line 4,638: Line 4,627:  
|
 
|
 
|-
 
|-
|Lipoma||Disease||
+
|NF1
 +
|
 
|
 
|
 
|
 
|
Line 4,647: Line 4,637:  
|
 
|
 
|-
 
|-
|Angiolipoma||Disease||
+
|SUZ12
 +
|
 
|
 
|
 
|
 
|
Line 4,656: Line 4,647:  
|
 
|
 
|-
 
|-
|Liposarcoma||Disease||
+
|ERG
 +
|
 
|
 
|
 
|
 
|
Line 4,665: Line 4,657:  
|
 
|
 
|-
 
|-
|Pseudoangiomatous stromal hyperplasia||Disease||
+
|EST2
 +
|
 
|
 
|
 
|
 
|
Line 4,674: Line 4,667:  
|
 
|
 
|-
 
|-
|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)||Disease||
+
|RPS14
 +
|
 
|
 
|
 
|
 
|
Line 4,683: Line 4,677:  
|
 
|
 
|-
 
|-
|Follicular lymphoma||Disease||
+
|RB1
 +
|
 
|
 
|
 
|
 
|
Line 4,692: Line 4,687:  
|
 
|
 
|-
 
|-
|Diffuse large B-cell lymphoma||Disease||
+
|MPL
 +
|
 
|
 
|
 
|
 
|
Line 4,701: Line 4,697:  
|
 
|
 
|-
 
|-
|Burkitt lymphoma||Disease||
+
|CHGA
 +
|
 
|
 
|
 
|
 
|
Line 4,710: Line 4,707:  
|
 
|
 
|-
 
|-
|Breast implant-associated anaplastic large cell lymphoma||Disease||
+
|CDH1
 +
|
 
|
 
|
 
|
 
|
Line 4,719: Line 4,717:  
|
 
|
 
|-
 
|-
|Gynaecomastia||Disease||
+
|SRSF2
 +
|
 
|
 
|
 
|
 
|
Line 4,728: Line 4,727:  
|
 
|
 
|-
 
|-
|Carcinoma in situ||Disease||
+
|DNMT1
 +
|
 
|
 
|
 
|
 
|
Line 4,737: Line 4,737:  
|
 
|
 
|-
 
|-
|Invasive carcinoma||Disease||
+
|PRDX2
 +
|
 
|
 
|
 
|
 
|
Line 4,746: Line 4,747:  
|
 
|
 
|-
 
|-
|Metastases to the breast||Disease||
+
|ASXL1
 +
|DONE
 
|
 
|
 
|
 
|
 +
|DONE
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|
 +
|-
 +
|MN1
 
|
 
|
|-
  −
|BRCA1/2-associated hereditary breast and ovarian cancer syndrome||Disease||
   
|
 
|
 
|
 
|
Line 4,764: Line 4,767:  
|
 
|
 
|-
 
|-
|Cowden syndrome||Disease||
+
|SF3A1
 +
|
 
|
 
|
 
|
 
|
Line 4,773: Line 4,777:  
|
 
|
 
|-
 
|-
|Ataxia-telangiectasia||Disease||
+
|EP300
 +
|
 
|
 
|
 
|
 
|
Line 4,782: Line 4,787:  
|
 
|
 
|-
 
|-
|Li-Fraumeni syndrome, TP53-associated||Disease||
+
|JARID2
 +
|
 
|
 
|
 
|
 
|
Line 4,791: Line 4,797:  
|
 
|
 
|-
 
|-
|Li-Fraumeni syndrome, CHEK2-associated||Disease||
+
|BRCA1
 +
|
 
|
 
|
 
|
 
|
Line 4,800: Line 4,807:  
|
 
|
 
|-
 
|-
|CDH1-associated breast cancer||Disease||
+
|BRCA2
 +
|
 
|
 
|
 
|
 
|
Line 4,809: Line 4,817:  
|
 
|
 
|-
 
|-
|PALB2-associated cancers||Disease||
   
|
 
|
 
|
 
|
 
|
 
|
 
|
 
|
|
  −
|
  −
|
  −
|-
  −
|Peutz-Jeghers syndrome||Disease||
   
|
 
|
 
|
 
|
Line 4,824: Line 4,826:  
|
 
|
 
|
 
|
 +
|-
 
|
 
|
 
|
 
|
|-
  −
|Neurofibromatosis type 1||Disease||
   
|
 
|
 
|
 
|
Line 4,835: Line 4,836:  
|
 
|
 
|
 
|
|-
   
|}
 
|}
 +
 +